

CORPORATE RELEASE

Valby, Denmark, February 18, 2026

Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties

1.	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Lars Bang	
2.	Reason for the notification		
a)	Position/status	Executive Vice President, Product Development & Supply	
b)	Initial notification/Amendment	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	H. Lundbeck A/S	
b)	LEI code	5493006R4KC2O15D3470	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	A-shares: DK0061804697	
b)	Nature of the transaction	Sale of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 36.0808	90,082
d)	Aggregated information - Aggregated volume - Price	DKK 3,250,230.63	
e)	Date of the transaction	2026-02-17	
f)	Place of the transaction	NASDAQ Copenhagen XCSE	

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities mean inter alia:

- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.

Contacts

Jens Høyer
Vice President, Head of Investor Relations
JSHR@lundbeck.com
+45 30 83 45 01

Anders Crillesen
Head of Media Relations, Corp. Communication
AECE@lundbeck.com
+45 29 79 12 86

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.